The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Open accessAbstract
BACKGROUND: Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS: We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1:1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival. RESULTS: Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab-dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P<0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P<0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab-dacarbazine group. CONCLUSIONS: Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, approximately 20% of patients who received ipilimumab achieved long-term survival greater than three years, with survival of 10 years noted for some patients (38,42).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
In the citing paper
“Ipilimumab (anti-CTLA4) was the first ICT to gain FDA approval in 2011 for the treatment of metastatic melanoma, on the basis of phase III trials demonstrating improvements in overall survival compared with vaccine or chemotherapy (37,38).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [38]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationToxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Final Version of 2009 AJCC Melanoma Staging and Classification
Balch, C. M., Gershenwald, J. E., Soong, S.-J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4799 · Cited by 4,653
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationAtkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043
Eguchi, S., Takatsuki, M., Soyama, A., Hara, T., Hidaka, M., Muraoka, I., & Kanematsu, T. (2011) · Hepatogastroenterology · doi:10.5754/hge11589 · Cited by 1,756
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270
Self-citationWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Self-citationImmunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 634
Weber, J. S., Thompson, J. A., Hamid, O., Minor, D. R., Amin, A., Ron, I. G., Ridolfi, R., Assi, H. I., Maraveyas, A., Berman, D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1024 · Cited by 566
Self-citationImproved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R. A., Anderson, A., Humphrey, R. W., Blumenstein, B. A., Old, L. J., & Wolchok, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 517
Self-citationAtkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506
Self-citationFong, L. H., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 320
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309
Self-citationHersh, E. M., O'Day, S. J., Powderly, J. D., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 305
Self-citationFalkson, C. I., Ibrahim, J. G., Kirkwood, J. M., Coates, A. S., Atkins, M. B., & Blum, R. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1743 · Cited by 302
Current systemic therapy for metastatic melanoma
Agarwala, S. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.25 · Cited by 172
Rusthoven, J. J., Quirt, I. C., Iscoe, N. A., McCulloch, P. B., James, K. W., Lohmann, R. C., Jensen, J., Burdette-Radoux, S., Bodurtha, A. J., Silver, H. K. B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2083 · Cited by 168
MOKYR, M. B., Kalinichenko, T. V., Gorelik, L., & Bluestone, J. A. (1998) · PubMed · Cited by 130
Robert, C., & Ghiringhelli, F. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0028 · Cited by 128
Self-citationBedikian, A. Y., Johnson, M. M., Warneke, C. L., Papadopoulos, N. E., Kim, K., Hwu, W., McIntyre, S. E., & Hwu, P. (2008) · Cancer Investigation · doi:10.1080/07357900802027073 · Cited by 79
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma
Frosch, P. J., Czarnetzki, B. M., Macher, E., Grundmann, E., & Gottschalk, I. (1979) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf00410649 · Cited by 36
Hepatic vascular lesions associated with dacarbazine treatment.
Greenstone, M. A., Dowd, P. M., Mikhailidis, D. P., & Scheuer, P. J. (1981) · BMJ · doi:10.1136/bmj.282.6278.1744 · Cited by 34
Dacarbazine (DTIC)-induced human liver damage light and electron-microscopic findings.
Dancygier, H., Runne, U., Leuschner, U., Milbradt, R., & Claßen, M. (1983) · PubMed · Cited by 22
Targeted Therapies in Metastatic Melanoma: Toward a Clinical Breakthrough?
Julia, F., Thomas, L., Dumontet, C., & Dalle, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794479834 · Cited by 13
Self-citationSchmidt, H., Hamid, O., Nissan, A., Guida, M., Aamdal, S., Hansson, J., Ridolfi, R., Berman, D., & Chasalow, S. D. (2009) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(09)71948-2 · Cited by 5
Research works printed but not linked: 1
- Mokyr MB, 1998, Cancer Res, 58, 5301
Cited by
Sorted by citations
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationCancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Metadata
- Authors
- Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H., Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T.-T., Humphrey, R., Hoos, A., & Wolchok, J. D.
- Affiliations
- Institut Gustave Roussy (FR)
- Hôpital Lyon Sud (FR)
- Dnipro State Medical University (UA)
- Angeles Clinic and Research Institute (US)
- Moffitt Cancer Center (US)
- Cliniques Universitaires Saint-Luc (BE)
- European Institute of Oncology (IT)
- Hôpital de la Timone (FR)
- Mid Essex Hospital Services NHS Trust (GB)
- Oncology Specialists (US)
- University of Siena (IT)
- Christian-Albrechts-Universität zu Kiel (DE)
- Hadassah Medical Center (IL)
- Medical University of Vienna (AT)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-06-30
- Volume
- 364
- Issue
- 26
- Pages
- 2517-2526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2123363005
- Cited by
- 4,496
- References
- 29
- Citations by year
- 2026: 58 · 2025: 99 · 2024: 148 · 2023: 173 · 2022: 213 · 2021: 249 · 2020: 289 · 2019: 283 · 2018: 374 · 2017: 415 · 2016: 466 · 2015: 476 · 2014: 400 · 2013: 392 · 2012: 346
- FWCI
- 195.50
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, dacarbazine, metastatic melanoma, combination immunotherapy, CTLA-4 blockade, overall survival, adverse events, liver dysfunction, maintenance therapy, immune-related adverse events, immune checkpoint inhibitors, progression-free survival
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Double-Blind Method, Female, Humans, Liver Function Tests, Male, Melanoma, Middle Aged, Proportional Hazards Models, Disease Progression, Antineoplastic Agents, Alkylating, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
